PDF herunterladen
Thromb Haemost 1991; 65(03): 275-279
DOI: 10.1055/s-0038-1648134
Original Article
Schattauer GmbH Stuttgart

Correlation between Baseline Plasminogen Activator Inhibitor Levels and Clinical Outcome during Therapy with Tissue Plasminogen Activator for Acute Myocardial Infarction

David C Sane
The Division of Cardiology, Department of Medicine, Duke University, Durham, NC; the Departments of Medicine and Biochemistry, University of Vermont, Burlington, VT; the Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor; Christ Hospital, Cincinnati; the Riverside Methodist Hospital, Columbus; and the Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
David C Stump
The Division of Cardiology, Department of Medicine, Duke University, Durham, NC; the Departments of Medicine and Biochemistry, University of Vermont, Burlington, VT; the Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor; Christ Hospital, Cincinnati; the Riverside Methodist Hospital, Columbus; and the Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
Eric J Topol
The Division of Cardiology, Department of Medicine, Duke University, Durham, NC; the Departments of Medicine and Biochemistry, University of Vermont, Burlington, VT; the Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor; Christ Hospital, Cincinnati; the Riverside Methodist Hospital, Columbus; and the Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
Kristina N Sigmon
The Division of Cardiology, Department of Medicine, Duke University, Durham, NC; the Departments of Medicine and Biochemistry, University of Vermont, Burlington, VT; the Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor; Christ Hospital, Cincinnati; the Riverside Methodist Hospital, Columbus; and the Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
Dean J Kereiakes
The Division of Cardiology, Department of Medicine, Duke University, Durham, NC; the Departments of Medicine and Biochemistry, University of Vermont, Burlington, VT; the Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor; Christ Hospital, Cincinnati; the Riverside Methodist Hospital, Columbus; and the Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
Barry S George
The Division of Cardiology, Department of Medicine, Duke University, Durham, NC; the Departments of Medicine and Biochemistry, University of Vermont, Burlington, VT; the Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor; Christ Hospital, Cincinnati; the Riverside Methodist Hospital, Columbus; and the Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
Susan J Mantell
The Division of Cardiology, Department of Medicine, Duke University, Durham, NC; the Departments of Medicine and Biochemistry, University of Vermont, Burlington, VT; the Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor; Christ Hospital, Cincinnati; the Riverside Methodist Hospital, Columbus; and the Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
Elizabeth Macy
The Division of Cardiology, Department of Medicine, Duke University, Durham, NC; the Departments of Medicine and Biochemistry, University of Vermont, Burlington, VT; the Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor; Christ Hospital, Cincinnati; the Riverside Methodist Hospital, Columbus; and the Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
Désiré Collen
The Division of Cardiology, Department of Medicine, Duke University, Durham, NC; the Departments of Medicine and Biochemistry, University of Vermont, Burlington, VT; the Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor; Christ Hospital, Cincinnati; the Riverside Methodist Hospital, Columbus; and the Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
Robert M Califf
The Division of Cardiology, Department of Medicine, Duke University, Durham, NC; the Departments of Medicine and Biochemistry, University of Vermont, Burlington, VT; the Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor; Christ Hospital, Cincinnati; the Riverside Methodist Hospital, Columbus; and the Center for Thrombosis and Vascular Research, University of Leuven, Belgium
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 07. Juni 1990

Accepted after revision 06. Oktober 1990

Publikationsdatum:
02. Juli 2018 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints

Summary

Baseline plasminogen activator inhibitor (PAI) levels were examined for their influence on the responses to thrombolysis with recombinant tissue plasminogen activator (rt-PA) administered for acute myocardial infarction during the Thrombolysis and Myocardial Infarction (TAMI)-I study. Baseline PAI activity was 19 ± 21 IU/ml (normal <5 IU/ml) and baseline PAI-1 antigen 54 ± 53 ng/ml (normal 27 ± 16 ng/ml), confirming previous findings of elevated PAI levels during acute myocardial infarction. Among clinical outcomes, lower PAI-1 antigen levels correlated weakly with greater patency at the 90 min angiogram. Thus, high baseline plasma PAI-1 levels may be detrimental to reperfusion with t-PA. There was no correlation with other major in-hospital clinical outcomes including reocclusion at the 7-10 day angiogram, survival to discharge, or bleeding. During the follow up period of 2.0 ± 0.4 years, no relationship between baseline PAI levels and post-discharge reinfarction was observed.

 

  • REFERENCES

  • 1 Wilcox RG, Olsson CG, Skene AM, von der Lippe G, Jensen G, Hampton JR. ASSET Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988 2. 525-530
    PubMedGoogle Scholar
  • 2 TIMI Study Group. The Thrombolysis in Myocardial Infarction trial: phase I findings. N Engl J Med 1985 312. 932-936
    PubMedGoogle Scholar
  • 3 Topol EJ, Califf RM, George BS, Kereiakes DJ, Abbottsmith CW, Candela RJ, Lee KL, Pitt B, Stack RS, O’Neill WW. the TAMI Study Group A multicenter randomized trial of intravenous recombinant tissue plasminogen activator and immediate versus deferred angioplasty in acute myocardial infarction. N Engl J Med 1987 317. 581-588
    PubMedGoogle Scholar
  • 4 Verstraete M, Bernard R, Bory M, Brower RW, Collen D, de Bono DP, Erbel R, Huhmann W, Lennane RJ, Lubsen J, Mathey D, Meyer J, Michels HR, Rutsch W, Schartl M, Schmidt W, Uebis R, von Essen R. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1985; 1: 842-847
    PubMedGoogle Scholar
  • 5 Ellis SG, Topol EJ, George BS, Kereiakes DJ, Debowey D, Sigmon KN, Pickel A, Lee KL, Califf RM. Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator. Circulation 1989; 80: 1159-1165
    CrossrefPubMedGoogle Scholar
  • 6 Kerins DM, Roy L, Fitzgerald GA, Fitzgerald DJ. Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. Circulation 1989; 80: 1718-1725
    CrossrefPubMedGoogle Scholar
  • 7 Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase: Evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol 1987; 10: 527-529
    CrossrefPubMedGoogle Scholar
  • 8 Lee CD, Mann KG. Activation/inactivation of human factor V by plasmin. Blood 1989; 73: 185-190
    PubMedGoogle Scholar
  • 9 Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. In: Progress in Hemostasis and Thrombosis. Vol 9 Coller BS. (ed): W. B. Saunders Co; Philadelphia, PA: 1989: 87-115
  • 10 Hamsten A, Wiman B, De Faire U, Blomback M. Increased levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563
    CrossrefPubMedGoogle Scholar
  • 11 Nilsson I, Lungher H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 1985; 290: 1453-1456
    CrossrefPubMedGoogle Scholar
  • 12 Landefeld CS, Cook EF, Hatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987; 82: 703-713
    CrossrefPubMedGoogle Scholar
  • 13 Califf RM, Topol EJ, George BS, Boswick JM, Abbottsmith C, Sigmon KN, Candela R, Masek R, Kereiakes D, O’Neill WW, Stack RS, Stump D. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in the treatment of acute myocardial infarction. Am J Med 1988; 85: 353-359
    CrossrefPubMedGoogle Scholar
  • 14 Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
    PubMedGoogle Scholar
  • 15 Declerck PJ, Alessi M-C, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-225
    PubMedGoogle Scholar
  • 16 Stump DC, Topol EJ, Chen AB, Hopkins A, Collen D. Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator. Thromb Haemostas 1988; 59: 133-137
    PubMedGoogle Scholar
  • 17 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestim-mung des Fibrinogens. Acta Haematol 1957; 37: 237-246
    PubMedGoogle Scholar
  • 18 Vermylen C, DeVreker RA, Verstraete M. A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT-test). Clin Chem Acta 1963; 8: 418-424
    CrossrefPubMedGoogle Scholar
  • 19 Rampling MW, Gaffney PJ. The sulphite precipitation method for fibrinogen measurement: its use on small sample in the presence of fibrinogen degradation products. Clin Chim Acta 1976; 67: 43-52
    CrossrefPubMedGoogle Scholar
  • 20 Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemostas 1985; 54: 684-687
    PubMedGoogle Scholar
  • 21 Merskey C, Lalezari P, Johnson AJ. A rapid, simple, sensitive method for measuring fibrinolytic split products in human serum. Proc Soc Exp Biol Med 1969; 131: 871-875
    CrossrefPubMedGoogle Scholar
  • 22 Stump DC, Califf RM, Topol EJ, Sigmon K, Thornton D, Masek R, Anderson L, Collen D. Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator: Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. Circulation 1989; 80: 1222-1230
    CrossrefPubMedGoogle Scholar
  • 23 Almer L-O, Ohlin H. Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction. Thromb Res 1987; 47: 335-339
    CrossrefPubMedGoogle Scholar
  • 24 Juhan-Vague I, Moerman B, DeCock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathologic conditions. Thromb Res 1984; 33: 523-530
    CrossrefPubMedGoogle Scholar
  • 25 Kluft C, Verheijen JH, Jie AFH, Rijken DC, Preston FE, Sue-Ling HM, Jespersen J, Aasen AD. The postoperative fibrinolytic shutdown: A rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest 1985; 45: 605-610
    CrossrefPubMedGoogle Scholar
  • 26 Kruithof EKO, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: Development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645-1653
    PubMedGoogle Scholar
  • 27 Aillaud MF, Pignol F, Alessi MC, Harle JR, Escande M, Mongin M, Juhan-Vague I. Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebrand factor, factor VIII:C, and in erythrocyte sedimentation rate with age. Thromb Haemostas 1986; 55: 330-332
    PubMedGoogle Scholar
  • 28 Kruithof EKO, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913
    PubMedGoogle Scholar
  • 29 Lucore CL, Sobel BE. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation 1988; 77: 660-669
    CrossrefPubMedGoogle Scholar
  • 30 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387
    PubMedGoogle Scholar
  • 31 Stump D, Topol E, Sigmon K, Stoddard M, Califf R. Pronounced sensitivity of blacks to tissue-type plasminogen activator (rt-PA) for acute myocardial infarction (abstract). Circulation 1988; 78: 275
    PubMedGoogle Scholar
  • 32 Barbash GI, Hod H, Roth A, Miller HI, Rath S, Zahav YH, Modan M, Zivelin A, Laniado S, Seligsohn U. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1989; 64: 1231-1235
    CrossrefPubMedGoogle Scholar
  • 33 Lucore CL, Fujii S, Sobel BE. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration. Circulation 1989; 79: 1204-1213
    CrossrefPubMedGoogle Scholar
  • 34 Hamsten A, Walldius G, Szamosi A, Blomback M, de Faire U, Dahlen G, Landou C, Wiman B. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-8
    PubMedGoogle Scholar
  • 35 Jang I-K, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 1989 79. 920-928
    PubMedGoogle Scholar